# Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies

> **NCT05397496** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 61 (actual)

## Conditions studied

- B-cell Non-Hodgkin Lymphoma (B-NHL)
- B-cell Acute Lymphoblastic Leukemia (B-ALL)

## Interventions

- **BIOLOGICAL:** PIT565

## Key facts

- **NCT ID:** NCT05397496
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-03
- **Primary completion:** 2026-08-20
- **Final completion:** 2026-08-20
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05397496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05397496, "Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT05397496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*